Clinical Trial Objectives, page-18

Much appreciated slashj. In essence, reading your clarifications, SRX was not participating in first line treatments anyway so the question becomes what p/e is appropriate? Anything over 40 times has proven historically dangerous even for radio stocks, Xerox on its prime etc so if the bullishness was based on this study proving it a wonder technique and cure all then this is not the case. Now below 30 times so back to reality I guess.